Biomodels has developed a comprehensive platform supporting preclinical oncology studies. At the base of the platform is our experience with established models; these include multiple cell lines (for each of the most commonly studied neoplasms) with well-characterized in vitro cytotoxicity profiles to standard of care agents. This effort allows us to rapidly evaluate the efficacy agents against relevant models while also developing a parallel clinical marker strategy.  As part of this effort, we have established an in vitro tumor bank to allow target profiling. In this, the tumor forming capability and drug responsiveness of each cell line has also been assessed in vivo and is linked to matched tissue samples (tumors with associated protein, RNA, DNA, and serum) to facilitate baseline comparisons to client compounds in efficacy and mechanism of action studies.